Parallel Advisors LLC Buys 3,742 Shares of Novartis AG $NVS

Parallel Advisors LLC raised its stake in shares of Novartis AG (NYSE:NVS) by 29.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,366 shares of the company’s stock after buying an additional 3,742 shares during the period. Parallel Advisors LLC’s holdings in Novartis were worth $2,500,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NewEdge Advisors LLC increased its position in Novartis by 0.5% during the first quarter. NewEdge Advisors LLC now owns 75,954 shares of the company’s stock valued at $11,602,000 after acquiring an additional 414 shares during the last quarter. First Nebraska Trust Co bought a new position in Novartis in the first quarter valued at about $277,000. Henshaw Capital LLC boosted its position in Novartis by 152.7% in the first quarter. Henshaw Capital LLC now owns 12,295 shares of the company’s stock worth $1,878,000 after purchasing an additional 7,430 shares during the last quarter. Glenmede Trust Co. NA boosted its position in Novartis by 16.0% in the first quarter. Glenmede Trust Co. NA now owns 63,066 shares of the company’s stock worth $9,633,000 after purchasing an additional 8,680 shares during the last quarter. Finally, Axiom Investment Management LLC bought a new stake in shares of Novartis during the 1st quarter valued at about $508,000. 13.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Citigroup restated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $141.20.

Trending Headlines about Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate to $8.82 from $8.75, bringing the forecast close to the broader consensus estimate of $8.85. It also increased its Q2 2027 estimate to $2.52 from $2.45 and Q2 2028 to $2.71 from $2.65, suggesting some confidence in earnings growth in those periods. Novartis earnings estimate report
• Neutral Sentiment: Zacks projects Novartis EPS of $9.67 for FY2027 and $10.62 for FY2028. While these figures imply continued earnings expansion from the FY2026 forecast, the FY2028 projection was reduced from $10.91, limiting the positive impact of the longer-term growth outlook. Novartis earnings estimate report
• Negative Sentiment: Analysts lowered several estimates, including Q3 2026 EPS to $2.22 from $2.30, Q4 2026 to $2.20 from $2.23, Q1 2027 to $2.31 from $2.41, Q3 2027 to $2.44 from $2.49, and FY2027 to $9.67 from $9.73. The cuts point to weaker near- and medium-term earnings expectations and may weigh more heavily than the limited upgrades. Novartis earnings estimate report

Novartis Price Performance

Shares of Novartis stock opened at $154.26 on Friday. The firm has a market cap of $294.35 billion, a PE ratio of 23.27, a PEG ratio of 2.64 and a beta of 0.45. The stock has a 50 day moving average of $152.87 and a 200 day moving average of $153.08. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis AG has a 12 month low of $114.38 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. On average, research analysts expect that Novartis AG will post 8.86 EPS for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.